- Lobbying
- Lobbying by Ipsen Biopharmaceuticals Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Kristine Blackwood | 4/10-6/15:DepDir,ConOversight,HHS;1/09-4/10: ChfCon, Sen.Com.Aging; 1/7-12/08: InvestigCon,House Energy&Commerce Com.; 6/05-1/07: USDOJ Of Leg. Affairs; 11/03-06/05: HealthCareFraud Coord,ExecOff,US Attys,USDOJ; 6/94-11/03: Asst. US Atty,CenDistrCA |
Kevin O'Neill | n/a |
Daniel Kracov | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q3 Report
Termination
Q2 Report
Q1 Report
Registration
Issue(s) they said they’d lobby about: Issues related to FDA oversight..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate